{
  "question_stem": {
    "en": "A 30-year-old man comes to the emergency department with sudden onset of severe headache and confusion. He has a history of autosomal dominant polycystic kidney disease. Neurological examination shows no meningeal signs or focal neurological deficits. CT scan of the head reveals blood in the subarachnoid space. The patient is admitted to the critical care unit for further management. On the fifth day after admission, he experiences new-onset weakness in the right arm and leg.",
    "zh": "一名30岁男性因突发剧烈头痛和意识模糊来到急诊科。他有常染色体显性遗传性多囊肾病病史。神经系统检查未见脑膜刺激征或局灶性神经功能缺损。头部CT扫描显示蛛网膜下腔出血。患者被收治入重症监护室进行进一步治疗。入院第五天，他出现新发右侧胳膊和腿无力。"
  },
  "question": {
    "en": "Which of the following medications could have most likely prevented the neurological complications this patient developed in the hospital?",
    "zh": "以下哪种药物最有可能预防该患者在住院期间发生神经系统并发症？"
  },
  "options": {
    "A": {
      "en": "ACE inhibitor",
      "zh": "ACE抑制剂"
    },
    "B": {
      "en": "Beta-adrenergic blocker",
      "zh": "β-肾上腺素能阻滞剂"
    },
    "C": {
      "en": "Calcium channel blocker",
      "zh": "钙通道阻滞剂"
    },
    "D": {
      "en": "Central sympatholytic",
      "zh": "中枢性交感神经抑制剂"
    },
    "E": {
      "en": "Nitrate",
      "zh": "硝酸酯类"
    },
    "F": {
      "en": "Osmotic diuretic",
      "zh": "渗透性利尿剂"
    },
    "G": {
      "en": "Thiazide diuretic",
      "zh": "噻嗪类利尿剂"
    }
  },
  "correct_answer": "C",
  "explanation": {
    "en": "This patient with subarachnoid hemorrhage (SAH) developed new-onset focal neurological deficits 5 days after his initial symptoms; a presentation characteristic of delayed cerebral ischemia due to cerebral vasospasm. SAH is most often caused by the rupture of a saccular (berry) aneurysm, which occurs frequently in patients with autosomal dominant polycystic disease.\n\nCerebral vasospasm with subsequent ischemia is the most common complication of SAH and typically manifests 3-12 days after the initial incident with a change in mental status and/or new focal neurological deficits. Nimodipine, a selective calcium channel blocker, improves outcomes in patients with SAH by preventing or reducing the extent of ischemic neurological deficits caused by cerebral vasospasm. This neuroprotective effect is likely due to a combination of increased cerebral vasodilation and decreased calcium-dependent excitotoxicity.\n\n(Choices A and B) Enalapril (an ACE inhibitor) and labetalol (a beta-adrenergic blocker with some alpha-antagonist activity) can be used to control hypertension (lowering the chance of rebleeding) in patients after SAH. However, rebleeding usually occurs in the first 24 hours after SAH, and acute onset of new neurological deficits 5 days after SAH is more indicative of delayed ischemia due to cerebral vasospasm.\n\n(Choice D) Central sympatholytics (eg, methyldopa, clonidine) stimulate alpha-2A receptors centrally, resulting in a decrease in generalized sympathetic outflow and reduced blood pressure. They do not have a role in prevention of ischemic deficits due to cerebral vasospasm following SAH.\n\n(Choice E) Nitrates (eg, nitroglycerin, isosorbide mononitrate) are used as vasodilators primarily for the treatment of angina pectoris. In patients with a recent SAH, nitrates should be avoided because they can increase cerebral blood flow and intracranial pressure, which can worsen bleeding.\n\n(Choice F) Osmotic diuretics (eg, mannitol) are part of the treatment for increased intracranial pressure (ICP). Although hydrocephalus can be a complication of SAH and result in elevated ICP, it typically presents with a gradual change in level of consciousness accompanied by ocular changes (eg, downward eye deviation, miosis) rather than focal extremity deficits. Ventricular dilation on neuroimaging is diagnostic.\n\n(Choice G) Thiazide diuretics are a first-line therapy for essential hypertension in the outpatient setting. They are not indicated for use in preventing complications due to cerebral vasospasm following SAH.\n\nEducational objective:\nDelayed cerebral ischemia due to cerebral vasospasm usually presents 3-12 days after the initial subarachnoid hemorrhage (SAH) with an acute change in mental status and/or new focal neurological deficits. Nimodipine, a selective calcium channel blocker, improves outcomes in patients with cerebral vasospasm by inducing cerebral vasodilation and decreasing calcium-dependent excitotoxicity.",
    "zh": "该蛛网膜下腔出血 (SAH) 患者在出现初始症状5天后出现新发局灶性神经功能缺损；这是一种由脑血管痉挛引起的迟发性脑缺血的特征性表现。SAH 最常由囊状（浆果状）动脉瘤破裂引起，这种动脉瘤在常染色体显性遗传性多囊肾病患者中频繁发生。\n\n脑血管痉挛继发缺血是SAH最常见的并发症，通常在最初事件发生后3-12天出现，表现为精神状态改变和/或新的局灶性神经功能缺损。尼莫地平，一种选择性钙通道阻滞剂，通过预防或减少由脑血管痉挛引起的缺血性神经功能缺损的程度，改善SAH患者的预后。这种神经保护作用可能是由于脑血管扩张增加和钙依赖性兴奋性毒性降低的综合作用所致。\n\n（选项 A 和 B）依那普利（一种ACE抑制剂）和拉贝洛尔（一种具有一些α-受体拮抗剂活性的β-肾上腺素能阻滞剂）可用于控制SAH患者的高血压（降低再出血的几率）。然而，再出血通常发生在SAH后的24小时内，SAH后5天出现新发神经功能缺损更提示是由脑血管痉挛引起的迟发性缺血。\n\n（选项 D）中枢性交感神经抑制剂（如甲基多巴、可乐定）在中枢刺激α-2A受体，导致全身交感神经外流减少和血压降低。它们在预防SAH后脑血管痉挛引起的缺血性神经功能缺损方面没有作用。\n\n（选项 E）硝酸酯类（如硝酸甘油、单硝酸异山梨酯）主要用作血管扩张剂治疗心绞痛。在最近发生SAH的患者中，应避免使用硝酸酯类药物，因为它们会增加脑血流量和颅内压，从而加重出血。\n\n（选项 F）渗透性利尿剂（如甘露醇）是治疗颅内压增高 (ICP) 的一部分。虽然脑积水可能是SAH的并发症并导致ICP升高，但其通常表现为意识水平的逐渐变化，伴有眼部改变（如眼球向下偏斜、瞳孔缩小），而不是肢体局灶性缺损。神经影像学检查中脑室扩张具有诊断意义。\n\n（选项 G）噻嗪类利尿剂是门诊治疗原发性高血压的一线疗法。它们不适用于预防SAH后脑血管痉挛引起的并发症。\n\n教育目标：\n由于脑血管痉挛引起的迟发性脑缺血通常在最初的蛛网膜下腔出血 (SAH) 发生后3-12天出现，表现为精神状态的急性变化和/或新的局灶性神经功能缺损。尼莫地平，一种选择性钙通道阻滞剂，通过诱导脑血管扩张和降低钙依赖性兴奋性毒性，改善脑血管痉挛患者的预后。"
  },
  "summary": {
    "en": "This question tests knowledge of subarachnoid hemorrhage (SAH) complications, specifically delayed cerebral ischemia due to vasospasm, and the appropriate prophylactic treatment with calcium channel blockers like nimodipine. It also requires understanding the timing of complications and differentiating vasospasm from rebleeding.\n\nTo solve this question, recognize the timeline of 3-12 days post-SAH for vasospasm, identify the new focal neurological deficits, and recall that calcium channel blockers are used to prevent vasospasm. Rule out other medications based on their mechanism of action and indications.",
    "zh": "本题考察对蛛网膜下腔出血 (SAH) 并发症的了解，特别是由于血管痉挛引起的迟发性脑缺血，以及使用钙通道阻滞剂（如尼莫地平）进行适当的预防性治疗。它还需要了解并发症的时间以及区分血管痉挛和再出血。\n\n要解决这个问题，需要识别SAH后3-12天内发生血管痉挛的时间，确定新的局灶性神经功能缺损，并记住钙通道阻滞剂用于预防血管痉挛。根据其他药物的作用机制和适应症排除它们。"
  },
  "tags": "Subarachnoid hemorrhage; Cerebral vasospasm; Calcium channel blocker; Nimodipine; Neurology; Neurosurgery; Autosomal dominant polycystic kidney disease",
  "category": "Neuro",
  "question_id": "146",
  "has_exhibits": false,
  "exhibit_count": 0,
  "exhibit_files": [],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Neuro 23\\146",
  "extracted_at": "2025-11-05T15:16:14.260089",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T18:19:46.968192",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}